Harmony Biosciences Holdings (HRMY) Long-Term Deferred Tax (2022 - 2026)

Harmony Biosciences Holdings has disclosed Long-Term Deferred Tax across 5 years of filings, most recently posting $153.6 million for Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $153.6 million, down 21.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $153.6 million (down 21.13% YoY), and the FY2025 annual result was $149.7 million, down 21.38% from the prior year.
• Long-Term Deferred Tax came in at $153.6 million for Q1 2026 at Harmony Biosciences Holdings, up from $149.7 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $201.2 million in Q2 2025 to a low of $81.7 million in Q3 2022.
• The 5-year median for Long-Term Deferred Tax is $149.7 million (2025), against an average of $143.6 million.
• Across the five-year window, Long-Term Deferred Tax soared 92.55% in 2024 and retreated 21.38% in 2025, its largest moves.
• Harmony Biosciences Holdings' Long-Term Deferred Tax stood at $85.9 million in 2022, then surged by 67.74% to $144.2 million in 2023, then surged by 32.07% to $190.4 million in 2024, then declined by 21.38% to $149.7 million in 2025, then gained by 2.58% to $153.6 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $153.6 million (Q1 2026), $149.7 million (Q4 2025), and $157.1 million (Q3 2025), per Business Quant data.